A little more than two months after filing for approval of Vivitrex, Alkermes Inc. partnered the alcohol-dependence drug with Cephalon Inc. in a 50-50 profit-sharing deal worth an additional $480 million in up-front and milestone payments. (BioWorld Today)
PHILADELPHIA - A disease of epidemic proportions hit Room 103A at the Pennsylvania Convention Center on Wednesday, the last day of the Biotechnology Industry Organization's annual international convention here. (BioWorld Today)
For two years after gaining approval of its HIV product Fuzeon, Trimeris Inc. has worked to develop next-generation peptide fusion inhibitors, but now it will branch its HIV research into a whole new area - small molecules. (BioWorld Today)
After disappointing Phase III data for the lung cancer drug Xyotax, Cell Therapeutics Inc. has sold its one marketed product - Trisenox - to Cephalon Inc. for up to $170 million. (BioWorld Today)